Stonepine Capital Management LLC Takes Position in Y-mAbs Therapeutics, Inc. $YMAB

Key Points

• Stonepine Capital Management LLC acquired a new stake in Y-mAbs Therapeutics, purchasing 131,160 shares valued at approximately $581,000, representing about 0.29% ownership of the company.
• Several institutional investors have recently increased their positions in Y-mAbs, with 70.85% of the stock now owned by hedge funds and other institutions, indicating strong interest in the company.
• Y-mAbs Therapeutics faced negative analyst ratings, with several firms downgrading their ratings and setting a target price of $8.60, reflecting a pessimistic outlook on the stock.

Stonepine Capital Management LLC purchased a new position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 131,160 shares of the company's stock, valued at approximately $581,000. Stonepine Capital Management LLC owned 0.29% of Y-mAbs Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in YMAB. JPMorgan Chase & Co. boosted its position in Y-mAbs Therapeutics by 221.9% during the 4th quarter. JPMorgan Chase & Co. now owns 97,660 shares of the company's stock worth $765,000 after purchasing an additional 67,325 shares during the period. Geode Capital Management LLC boosted its position in Y-mAbs Therapeutics by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 822,309 shares of the company's stock worth $6,440,000 after purchasing an additional 8,820 shares during the period. Wells Fargo & Company MN boosted its position in Y-mAbs Therapeutics by 54.1% during the 4th quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock worth $137,000 after purchasing an additional 6,131 shares during the period. Renaissance Technologies LLC boosted its position in Y-mAbs Therapeutics by 371.7% during the 4th quarter. Renaissance Technologies LLC now owns 131,600 shares of the company's stock worth $1,030,000 after purchasing an additional 103,700 shares during the period. Finally, Barclays PLC boosted its position in Y-mAbs Therapeutics by 9.6% during the 4th quarter. Barclays PLC now owns 75,862 shares of the company's stock worth $594,000 after purchasing an additional 6,640 shares during the period. 70.85% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Morgan Stanley set a $8.60 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, August 5th. Brookline Capital Management lowered shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 5th. Truist Financial set a $8.60 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, August 5th. Canaccord Genuity Group lowered shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and cut their price objective for the stock from $26.00 to $8.60 in a report on Tuesday, August 5th. Finally, Cantor Fitzgerald set a $8.60 price objective on shares of Y-mAbs Therapeutics and gave the stock a "neutral" rating in a report on Tuesday, August 5th. Eight research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Y-mAbs Therapeutics currently has a consensus rating of "Reduce" and an average target price of $9.62.

Y-mAbs Therapeutics Stock Performance

Shares of Y-mAbs Therapeutics stock traded up $0.01 during trading on Friday, reaching $8.55. The company had a trading volume of 117,916 shares, compared to its average volume of 528,841. The company has a market cap of $388.28 million, a price-to-earnings ratio of -17.09 and a beta of 0.57. The firm's fifty day moving average is $5.96 and its 200-day moving average is $5.18. Y-mAbs Therapeutics, Inc. has a fifty-two week low of $3.55 and a fifty-two week high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its earnings results on Friday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.20. The business had revenue of $19.52 million for the quarter, compared to analyst estimates of $18.40 million. Y-mAbs Therapeutics had a negative net margin of 26.03% and a negative return on equity of 24.60%. On average, research analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.